Tanvex BioPharma, Inc. (“Tanvex” or “the Company”, TWSE: 6541), the biosimilar-focused biopharmaceutical company and CDMO, today announced that its Board of Directors has appointed Stephen Lam as the Company’s Chief Executive Officer, effective September 5, 2024. Stephen succeeds Henry Chen, who shall remain the Chairman until the closing of Tanvex’s strategic alliance with Bora Pharmaceuticals Co., Ltd (“Bora”).

As a part of the new leadership initiated by Bora, Stephen Lam will be responsible for ensuring a successful integration, driving the Company’s strategic initiatives as well as overseeing Tanvex’s day-to-day operations, including its global CDMO operations and the commercialization of its biosimilar pipeline.

“We are thrilled to welcome Stephen to Tanvex’s leadership team,” commented Henry Chen. “His extensive experience in biologics operations and proven track record of driving operational excellence will be instrumental to advancing our CDMO capabilities. As a key aspect of our alliance with Bora, this appointment will help the Company expand its global presence and accelerate its growth, thereby taking Tanvex to new heights.”

“I am honored to take on the role of CEO at Tanvex. By integrating Tanvex’s established commercial biologics manufacturing with Bora’s strong reputation, industry leading quality, and proven process development expertise,” said Stephen Lam. “We can serve our customers no matter where they are in their drug development lifecycle, from First-In-Human studies through to commercial launch.”

With over 35 years in the biopharmaceutical industry at leading companies including Lonza, Amgen, and Patheon, Mr. Lam has built a strong track record of delivering results. More recently, he served as Vice President and General Manager, Head of Biologics at Thermo Fisher Scientific, one of the top 10 global CDMOs.